BACKGROUND: In this retrospective study, we investigated the efficacy and safety of radioimmunotherapy with (90)Yttrium- ibritumomab tiuxetan ((90)Y-RIT) in 9 @entity1 with recurrent @entity706 ( @entity706 ) who were treated in a consolidation setting after having achieved complete (CR) or partial remission (PR) with @entity3118 , @entity786 and Rituximab (FCR). METHODS: The median age was 63  years (range 46-77). All @entity1 were relapsed with histologically confirmed @entity2225 -positive (grade 1 or 2) @entity706 , at relapse they received FCR every 28  days: F (25  mg/m(2)x 3  days), C (1 gr/m(2)  day 1) and R (375  mg/m(2)  day 4) for 4  cycles. Those who achieved at least a PR with <25  % bone marrow involvement were treated with (90)Y-RIT 11.1 or 14.8  MBq/Kg, at 3  months after completing FCR. @entity1 underwent a further restaging at 12  weeks after (90)Y-RIT with a total body CT scan, FDG-PET/CT and bilateral bone marrow biopsy. RESULTS: Nine @entity1 completed the treatment: FCR followed by (90)Y-RIT (6 @entity1 at 14.8  MBq/Kg, 3 @entity1 at 11.1  MBq/Kg). After FCR, 7 @entity1 obtained CR and 2 PR; after (90)Y-RIT 2 @entity1 in PR converted to CR 12  weeks later. With a median follow up of 95  months (range 20-114) since FCR and 88  months (range 13-104) since (90)Y-RIT 3 deaths were not related to @entity706 ; all 3 deceased @entity1 obtained CR before (90)Y-RIT and died still in CR. The median overall ( @entity3012 ) and progression free survival (PFS) have not been reached, in this analysis both @entity3012 or PFS are 67  % at 7.5  year. The most common grade 3 or 4 adverse events were hematologic. CONCLUSIONS: These results confirm the long term efficacy and safety of 4  cycles of FCR followed by (90)Y-RIT in relapsed grades 1 and 2 @entity706 and suggest that this regimen could be a therapeutic option for this setting of @entity1 , specially at age of 60-75 with no unexpected @entity137 .

Long term efficacy and safety of @entity3118 , XXXX and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 @entity706 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'FL', 'follicular lymphoma'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['Cyclophosphamide'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['Fludarabine']
@entity786 :: (MESH:D003520,Chemical) :: ['Cyclophosphamide']
